Perspective Therapeutics Inc’s recently made public that its Chief Accounting Officer Hunt Jonathan Robert acquired Company’s shares for reported $22295.0 on Nov 13 ’25. In the deal valued at $2.03 per share,11,000 shares were bought. As a result of this transaction, Hunt Jonathan Robert now holds 59,800 shares worth roughly $0.14 million.
Then, Williamson Robert F III bought 9,498 shares, generating $19,946 in total proceeds. Upon buying the shares at $2.10, the Director now owns 9,864 shares.
Before that, Spoor Johan M. bought 22,026 shares. Perspective Therapeutics Inc shares valued at $49,384 were divested by the Chief Executive Officer at a price of $2.24 per share. As a result of the transaction, Spoor Johan M. now holds 59,383 shares, worth roughly $0.14 million.
BTIG Research initiated its Perspective Therapeutics Inc [CATX] rating to a Buy in a research note published on October 10, 2025; the price target was $14. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. Scotiabank began covering CATX with “Sector outperform” recommendation on March 07, 2025. BofA Securities revised its rating on November 25, 2024. It rated CATX as “a Neutral” which previously was an “a Buy”.
Price Performance Review of CATX
On Tuesday, Perspective Therapeutics Inc [AMEX:CATX] saw its stock jump 3.17% to $2.28. Over the last five days, the stock has gained 2.70%. Perspective Therapeutics Inc shares have fallen nearly -74.44% since the year began. Nevertheless, the stocks have fallen -28.53% over the past one year. While a 52-week high of $7.95 was reached on 10/13/25, a 52-week low of $1.60 was recorded on 04/09/25.
Levels Of Support And Resistance For CATX Stock
The 24-hour chart illustrates a support level at 2.18, which if violated will result in even more drops to 2.08. On the upside, there is a resistance level at 2.37. A further resistance level may holdings at 2.47.
How much short interest is there in Perspective Therapeutics Inc?
A steep rise in short interest was recorded in Perspective Therapeutics Inc stocks on 2025-10-31, dropping by -0.19 million shares to a total of 6.58 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 6.78 million shares. There was a decline of -2.94%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 24, 2024 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $20 price target.
